<DOC>
	<DOCNO>NCT00003920</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody locate tumor cell deliver tumor-killing substance without harm normal cell . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . Sometimes transplanted cell make immune response body 's normal tissue . Cyclosporine may prevent happen . PURPOSE : Phase I trial study effectiveness radiolabeled monoclonal antibody plus cyclosporine peripheral stem cell transplantation treat patient metastatic breast cancer respond previous therapy .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Plus Cyclosporine Peripheral Stem Cell Transplantation Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine variation indium In 111 label 2IT-BAD monoclonal antibody 170 ( 111In-2IT-BAD-m170 ) pharmacokinetics therapy patient metastatic breast cancer . II . Determine therapeutic dose yttrium Y 90 label 2IT-BAD monoclonal antibody 170 ( 90Y-2IT-BAD-m170 ) base calculate radiation dosimetry normal nonmarrow tissue pharmacokinetic study 111In-2IT-BAD-m170 perform prior therapy course patient . III . Determine maximum tolerate , nonmarrow , normal tissue dose ( MTNTD ) 90Y-2IT-BAD-m170 patient 3 course cyclosporine plus autologous peripheral stem cell support give every 3 month . IV . Evaluate safety tumor response 111In/90Y-2IT-BAD-m170 therapy cyclosporine autologous peripheral stem cell MTNTD patient . OUTLINE : This dose escalation study yttrium Y 90 label 2IT-BAD monoclonal antibody 170 ( 90Y-2IT-BAD-m170 ) . Patients stratify accord risk base prior therapy ( standard combine chemotherapy v standard high dose combine chemotherapy bone marrow transplant stem cell support ) . All patient receive subcutaneous filgrastim ( G-CSF ) stem cell collection . Beginning 3 5 day start G-CSF , patient undergo apheresis either daily every day 4 8 procedure . Patients receive oral cyclosporine twice daily , start day 1 , 2 week . On day 4 , patient receive nonlabeled 2IT-BAD monoclonal antibody m170 IV 10-15 minute , follow 15 minute later indium In 111 label 2IT-BAD monoclonal antibody 170 ( 111In-2IT-BAD-m170 ) IV 10-15 minute . Patients undergo dosimetry image immediately , 3 hour later , day 1-4 day 7 postinjection . Patients receive nonlabeled monoclonal antibody IV 10-15 minute , follow 15 minute later In 111/Y 90 label 2IT-BAD monoclonal antibody 170 ( 111In/90Y-2IT-BAD-m170 ) IV 10-15 minute , undergo image pretherapy . Patients also receive cyclosporine , administer pretherapy , total 35 day , plus autologous stem cell support follow G-CSF course . Cohorts 3-9 patient receive escalate dos 111In/90Y-2IT-BAD-m170 . Patients proceed next dose level 3 patient high risk group reach maximum tolerate , nonmarrow , normal tissue dose ( MTNTD ) least 3 month second course therapy . Therapy repeat every 3 month 3 course . PROJECTED ACCRUAL : A total 18 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm refractory metastatic breast cancer Must either relapse failed achieve complete remission combination chemotherapy without stem cell marrow transplantation No CNS disease No generalized total mass liver involvement great 25 % volume No pulmonary metastasis involve great 25 % lung volume Tumor marker evidence metastatic disease physical exam radiography require patient bone disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 physiologic age 55 Menopausal status : Not specify Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 2000/mm3 Platelet count least 150,000/mm3 Arterial blood gas within normal limit age sex Hepatic : See Disease Characteristics Bilirubin great 1.3 mg/dL Renal : Creatinine great 1.5 mg/dL Cardiovascular : LVEF least 50 % MUGA Pulmonary : FEV1 FVC least 65 % predict Corrected diffuse capacity least 60 % Other : Adequate venous access Able tolerate apheresis , filgrastim ( GCSF ) , cyclosporine Human antimouse antibody ( HAMA ) negative No primary malignant neoplasm except curatively treat basal cell carcinoma surgically cure carcinoma situ cervix Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy No concurrent chemotherapy At least 1 year since prior high dose intensive marrow toxic therapy require stem cell bone marrow transplantation No pulmonary toxicity due prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy No concurrent radiotherapy No prior radiotherapy great 25 % total skeleton Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2000</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>